[junkie-button url=”http://infomeddnews.com/” style=”grey” size=”medium” type=”round” target=”_blank”] HOME [/junkie-button]
Medtronic plc (NYSE:MDT), today announced data from the first economic analysis conducted on the use of professional continuous glucose monitoring (CGM) in people with type 2 diabetes. Data from the study demonstrated significant cost avoidance to the healthcare system when used during a therapy change or when used at least twice per year. The results also reinforced the well-established clinical benefits of professional CGM use in people with type 2 diabetes. The study, published in the Journal of Medical Economics, retrospectively analyzed real-world data of over 5,600 people who used professional CGM in the United States using health insurance medical and pharmacy claims, enrollment data and laboratory data.
The company reports that the data demonstrated that over a period of one year after the use of professional CGM, patients saw a net improvement of A1C, a measure of average blood glucose, of 0.4 percent and that total healthcare costs associated with these patients did not increase significantly compared to those who did not use professional CGM. Additionally, when professional CGM was used during a change of a diabetes therapy such as moving from one diabetes medication to another, professional CGM users’ costs increased $3,300 less when compared to the control group. A similar economic benefit to the healthcare system ($3,700) was found for people using professional CGM two or more times per year even with no therapy change. In both cases, A1C was significantly improved.
Laura Stoltenberg, vice president and general manager of the Non-Intensive Diabetes Therapies business said, “As a global leader in value-based healthcare, Medtronic is committed to ensuring that care delivered to people with diabetes, a global epidemic accounting for more than $500 billion annually of global healthcare costs, demonstrably improves patient outcomes while lowering the total cost of care.” Regarding the findings, Stoltenberg said, “These findings suggest that professional CGM – like our iPro(TM)2 professional CGM – is not only an important therapy management tool that provides significant clinical benefits, but can also help alleviate the economic burden of type 2 diabetes on the healthcare system.”
Professional CGM technology helps optimize care by providing both clinicians and patients more complete insights into the link between lifestyle and glucose fluctuations – insights that fingersticks alone can miss. The iPro2 professional CGM system provides glucose recordings every five minutes for up to six days to provide an accurate and complete picture of glucose fluctuations.1,2 The iPro 2 professional CGM system remains one of the most widely used professional CGM products in the United States, and this analysis confirms and validates the value of using professional CGM to guide therapy optimization and to manage patients.
“Data from this study is compelling and adds to the growing body of clinical and now economic evidence demonstrating the significant benefits of professional CGM in patients with type 2 diabetes,” said Francine Kaufman, M.D., chief medical officer, Diabetes Group, Medtronic. “As suggested in the American Association of Clinical Endocrinologists (AACE) Consensus Statement on the use of professional CGM, it is a powerful tool to help get patients to their A1C target and reduce glycemic variability. These results also suggest that professional CGM can help reduce the escalating costs of type 2 diabetes.”